Course Directors: Mellar P. Davis, MD, FCCP, FAAHPM, Mary Lynn McPherson, PharmD, MA, MDE, BCPS, CPE
At the end of this educational activity, participants should be able to:
- Describe the therapeutic benefits of buprenorphine and highlight indications for its use in acute, chronic and cancer pain.
- Explain interactions of buprenorphine with other opioids.
- Explain the appropriate application of buprenorphine in pain patients and those with co-morbid substance use disorder.
- Explain the concepts and practice of micro-dosing, rotation and titration.
- Recognize the legal and regulatory implications of prescribing opioids that arise when treating individuals in pain.
- Explain the basic pharmacology of buprenorphine and utilize and promote evidence-based approaches for clinical treatment.
- Describe the various delivery methods for buprenorphine in the management of pain.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Weston Medical Publishing. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring activity for a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Boston University School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
Jacqueline Cleary is a speaker for Genomind, a consultant and on the AcelRx Pharmaceuticals Advisory Board and a consultant for Remitigate. She does plan on discussing unlabeled/investigational uses of a commercial product.
Jeffrey Bettinger is on the Hisamitsu America, Inc. and PainScript LLC. Advisory Boards.
Kathleen Broglio does plan on discussing unlabeled/investigational uses of a commercial product.
Lynn Webster is a principal investigator for Cognifiscence and a consultant for BDSI, Clarity Science, Ensys.., KempPharm, Salix and Shionogi.
Gurpreet Singh Guilani does plan on discussing unlabeled/investigational uses of a commercial product.
Jordana Laks, MD, CME Reviewer, has no relevant financial relationships.
All other faculty/planners have no relevant financial relationships and do not plan on discussing unlabeled/investigational uses of a commercial product.
Claim your credit:
Please click here to register for BUPE2021.com to access presentations and CME details.
Or login in to access presentations and CME details.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
Off Label Statement: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The faculty have been asked to disclose this information when presented. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Cancellations: As the content is available on this website through the end of June, 2022, there are no refunds for cancellations however we will address hardships on a case by case basis. Substitutions of enrolled registrants must be made in writing. If for any reason this conference is cancelled, the conference organizers and sponsors do not accept responsibility for covering airfare, hotel or other costs incurred by conference registrants. The speakers and agenda of this program are subject to change without notice due to unforeseen circumstances beyond the control of conference presenters.
ADA Support: Weston Medical Publishing, LLC fully comply with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact our offices at 781-899-2702 Ext. 108 in order to receive services.
The Journal of Opioid Management presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.
The speakers and agenda of this program are subject to change without notice due to unforeseen circumstances beyond the control of conference presenters.